Among the different types of liver tumor, hepatocellular neoplasms predominate by far in both animals and man. Consequently, preneoplastic foci of altered hepatocytes (FAH), preceding both hepatocellular adenomas and carcinomas, represent the most prevalent form of hepatic preneoplasia observed in animals for a long time, and identified in human chronic liver diseases associated with, or predisposing to, hepatocellular carcinomas more recently. Morphological, microbiochemical, and molecular biological approaches in situ revealed striking similarities in specific changes of the cellular phenotype of preneoplastic FAH developing in experimental and human hepatocarcinogenesis, irrespective of whether this was elicited by chemicals, hormones, viruses or radiation. The advantage of using FAH for risk identification (aiming at primary cancer prevention) in long-term and medium-term carcinogenesis bioassays has been well documented, but quantitative morphometric approaches appear to be indispensable for an appropriate evaluation of both bioassays. The detection of phenotypically similar FAH in various animal models and in humans prone to develop or bearing hepatocellular carcinomas favors the extrapolation from data obtained in animals to humans. Moreover, the recently reported frequent finding of FAH in fine-needle biopsies of patients suffering from chronic liver diseases opens new perspectives for secondary prevention of human hepatocellular carcinoma.
INTRODUCTION
Preneoplastic foci of altered hepatocytes (FAH) have been known as the earliest emerging distinct phenotypic parenchymal changes indicating carcinogenic response in chemical hepatocarcinogenesis in rats and mice for almost 4 decades, and have been discussed as potential end-points in carcinogenicity testing since the early 80s (8) . Many research groups have used these lesions in mechanistic studies on hepatocarcinogenesis, and some groups have developed mediumterm carcinogenesis bioassays based on the predictive value of FAH (3, 18, 26, 27, 34, 36, 37) . It is evident, however, that there is a confusing variety of experimental approaches (Figure 1 ), which make a complete consensus on the interpretation of the results difficult (5, 7) .
In addition to innumerable chemical hepatocarcinogens inducing FAH in different animal species, FAH have been produced in rodents by oncogenic hepadnaviruses, Helicobacter hepaticus, transgenic oncogenes, certain hormones, and radiation with X-rays, neutrons or α-particles from thorotrast (5, 7) . To the best of our knowledge there is neither any hepatocarcinogenic agent which does not elicit FAH, nor is there any model of hepatocarcinogenesis without formation of these lesions prior to the manifestation of benign or malignant hepatocellular neoplasms. More recently, phenotypically similar preneoplastic lesions have also been identi-fied in human chronic liver diseases associated with, or predisposing to, HCC, irrespective of their aetiology including chronic viral infections and a few defined chemicals (1, 6, 9, 32) . The striking similarities in the phenotype of FAH across all species investigated appears to be of great advantage for both mechanistic studies and the extrapolation of observations in animals to human beings (6, 8) , notwithstanding the well known obstacles in interspecies comparisons of toxicodynamics, toxicogenomics, and pathobiological processes (15, 17) .
Although FAH have been widely used in carcinogenesis research and carcinogenicity testing, their potential for the evaluation of carcinogenesis bioassays has not been fully exploited. In addition to the identification of risk factors for neoplastic development, which is a prerequisite for primary prevention of cancer, the detection of preneoplastic changes in the human liver is a premise for new approaches to secondary prevention of liver cancer, which is one of the most frequent cancers worldwide.
Pathobiology of Hepatic Preneoplasia
As in many other tissues, preneoplasia and benign neoplasia in the liver parenchyma represent subsequent stages in a biologic continuum leading from the normal to the malignant phenotype. The earliest emerging types of FAH are composed of differentiated hepatocytes that show characteristic metabolic and molecular aberrations and gradually progress via various intermediate forms to the poorly differentiated neoplastic phenotype. Although there is a considerable phenotypic diversity and instability of FAH, results from several sequential studies in different models of hepatocarcinogenesis suggest that the various types of FAH do not 134 0192-6233/03$3.00+$0.00 Vol. 31, No. 1, 2003 HEPATIC PRENEOPLASIA AND CANCER PREVENTION 135 FIGURE 1.-Schematic presentation of various animal models of hepatic preneoplasia [modified from ref (7) ].
occur at random but are integral parts of 3 main preneoplastic hepatocellular lineages (4, 6) : the glycogenotic-basophilic cell lineage; its xenomorphic-tigroid cell variant; and the amphophilic-basophilic cell lineage ( Figure 2 ). After exposure to the majority of hepatocarcinogenic chemicals, especially to DNA-reactive compounds such as N -nitrosomorpholine, the glycogenotic-basophilic cell lineage prevails (8) . The focal excessive storage of glycogen (glycogenosis) is associated with characteristic enzymatic changes, including a decrease in the activities of glucose-6-phosphatase and adenylate cyclase, and an increase in the activity of the glucose-6-phosphate dehydrogenase and in the amount of the placental form of glutathione S-transferase (GSTP) (7, 8) . In addition to DNA-reactive chemicals, the predominant glycogenotic-basophilic and the xenomorphictigroid cell lineages develop after exposure of rodents to radiation, hepadnaviridae, transgenic oncogenes, and local hyperinsulinism (5, 6) . Biochemical and molecular biological studies in situ or in microdissected FAH from the glycogenotic-basophilic cell lineage revealed that the changes in energy metabolism characterizing these lesions initially indicate insulinomimetic effects of the oncogenic agents, which have been traced to an overexpression of the insulin receptor, the IGF-I receptor, the insulin receptor substrates-1/2, and other components of the insulinstimulated signal transduction pathway ( Figure 3 ) (4, 5). Insulin has also been shown to induce the expression of GSTP in primary cultures of rat hepatocytes (16) , but in FAH produced in rats by local hyperinsulinism this enzymatic alteration was not detected (10) . Cellular dedifferentiation during progression from glycogenotic to basophilic cell populations is associated with a downregulation in insulin signaling, and a gradual shift from anabolic to catabolic glucose metabolism providing energy for the ever increasing cell proliferation (4, 5) .
In contrast to the glycogenotic-basophilic and the xenomorphic-tigroid cell lineages, the amphophilicbasophilic cell lineage of hepatocarcinogenesis has hitherto mainly been observed after exposure of rodents to peroxisome proliferators that do not directly react with DNA, and also hepadnaviridae (4, 8, 25) . The biochemical pattern of the amphophilic FAH mimicks an effect of thyroid hormone, including a mitochondrial proliferation and activation of mitochondrial enzymes. In rodents, a number of the biologic activities of peroxisome proliferators including the steroid hormone dehydroepiandrosterone have been shown to be mediated by the peroxisome proliferator-activated receptor α (PPARα), a member of the nuclear receptor superfamily of steroids (14, 29) , which also mediate effects of the thyroid hormone 3,3,5-triiodo-L-thyronine (T 3 ) (12, 22) . Circumstantial evidence suggests that cross-talk between different signal transduction pathways related to insulinomimetic and thyromimetic actions of oncogenic agents may occur during carcinogenesis, and may also play an important role in chemoprevention (5) . This may explain some seemingly paradoxical effects of peroxisome proliferators, such as dehydroepiandrosterone, which inhibit hepatocarcinogenesis under certain experimental conditions, but act as hepatocarcinogens or hepatopromotors under other conditions (11, 24) .
Hepatic Preneoplasia in Long-Term Carcinogenesis Bioassays
In 1992, the International Agency for Research on Cancer in Lyon organized a meeting on Mechanisms of Carcinogenesis in Risk Identification (35) . In the consensus report of TOXICOLOGIC PATHOLOGY The tigroid basophilic cell lineage (to the right), originating from xenomorphic hepatocytes (X-cells), is characterized by cells with abundant highly ordered stacks of the rough endoplasmic reticulum and apparently represents a variant of the glycogenotic-basophilic cell lineage, occurring especially after low-dose treatment with hepatocarcinogens. The amphophilic cell lineage (to the left), which has hitherto mainly been described in rats treated with non-genotoxic peroxisome proliferators, and may include oncocytes in woodchucks chronically infected with the woodchuck hepatitis virus, consists of cells with a glycogen-poor cytoplasm containing granular-acidophilic (mitochondria and peroxisomes) and basophilic (ribosomes) components [from ref (4) ]. this meeting, it has been explicitly stated that there is general agreement that the induction of an increased incidence of FAH by a test compound provides additional evidence for carcinogenicity when only a borderline increase in the incidence of hepatic neoplasms is observed at the end of a 2-year carcinogenesis bioassay in rodents. Consequently, in bioassays conducted by the National Toxicology Program or in industrial laboratories, FAH have been recorded, and sometimes even graded, for many years (34) . However, a serious shortcoming of these efforts is that at least in most of the published literature, only the incidence of FAH (ie, the number of animals showing FAH) is given. As it is well known that the liver of almost all aged animals contains some FAH, significant differences in the incidence of FAH between treated animals and untreated concurrent controls can hardly be expected in long-term studies. Such differences will only be detected when the number and size of FAH is determined by morphometric approaches (20) . This also applies to the detection of FAH in subchronic studies regularly preceeding the chronic carcinogenesis bioassay. Advantage should be taken from the results of these routine checks.
The observation of a significant increase in the number and size of FAH in animals subchronically exposed to a test compound compared to those in untreated controls is a reliable indicator of hepatocarcinogenic response when persistence of the majority of the focal lesions can be demonstrated 4 weeks after stopping treatment (3, 7) . This experimental approach (stop protocol) may be regarded as a medium-term carcinogenesis bioassay in its own right, saving additional experimental manipulations, animals, costs, and time. In case of borderline results in the evaluation of FAH after subchronic exposure, modifications of the study protocol including interim sacrifices may improve investigation of the hepatocarcinogenic potential of the respective test compound. Considering the time and energy devoted to the 2-year carcinogenesis bioassays, additional morphometric studies on FAH at interim and terminal sacrifices should be seriously taken into account in future strategies for the Vol. 31, No. 1, 2003 HEPATIC PRENEOPLASIA AND CANCER PREVENTION 137 FIGURE 3.-Selected signal transduction pathways involved in hepatocarcinogenesis, particularly the insulin-stimulated ras-, raf-, mitogen activated signaling cascade (centre) and the glucagon-stimulated, adenylate cyclase-mediated pathway (to the left). AC, adenylate cyclase; GRB2, growth factor receptor binding protein-2; GSK-3, glycogen synthase kinase-3; ins, insulin; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like growth factor-II; IGF-IR, insulin-like growth factor-I receptor; IR, insulin receptor; IRS-1/2, insulin receptor substrate-1 and -2; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated extracellular signal-regulated kinase; PDK1, phosphoinositide-dependent protein kinase-1; PI3K, phosphatidyl-inositol-3-kinase; PKA, protein kinase A; PKB (=Akt), protein kinase B; PP1, protein phosphatase 1; mSOS, mammalian son of sevenless; py, phosphotyrosine [(from ref (5) ]. conduction and evaluation of these bioassays by both test laboratories and regulatory agencies.
Hepatic Preneoplasia in Medium-Term Carcinogenesis Bioassays
Based on the predictive value of preneoplastic FAH, several medium-term carcinogenesis bioassays have been pro-posed as a reliable means for identifying chemicals with hepatocarcinogenic potential (18, 34, 36, 37) . Advantages and disadvantages of these various approaches have been discussed in detail elsewhere (7, 18, 36) . The limitation of all of these bioassays to a certain target tissue is an obvious disadvantage for the identification of cancer risk factors in general, but the liver appears to offer a unique advantage in TOXICOLOGIC PATHOLOGY this respect because approximately 30% of all chemicals that were found to exert carcinogenic effects in rodents included the liver as a target organ. Using an experimental protocol originally proposed by Tsuda et al (33) the most extensive medium-term carcinogenesis bioassay has been conducted by Ito and colleagues (18) . This bioassay employs GSTPpositive FAH as an end point, and consists of initiation with a single dose of diethylnitrosamine (DEN) followed by the test compound for 6 weeks (from week 2 to week 8) and additional partial hepatectomy stimulating cell proliferation at week 3 (Figure 1) . In a summary report (18) including more than 170 test compounds (with and without previously determined DNA-reactivity), the authors stated that 90% of the hepatocarcinogens gave positive results ie, increased the number and size of GSTP-positive FAH; 22% of carcinogens other than established hepatocarcinogens gave also positive results. False-negative results were obtained with peroxisome proliferators. None of the compounds described to be noncarcinogenic showed positivity.
The protocol introduced by Oesterle and colleagues (26) is similar to that proposed by Tsuda et al (33) but avoids the strong animal strain by partial hepatectomy (using weanling rats with an intrinsically high cell proliferation) and extends the period of exposure to the test compound from 6 to 10 weeks (Figure 1) . Comparison of the number and size of FAH produced by the test compound alone with those developing after application of the test compound following initiation by a single dose of diethylnitrosamine (DEN), aims at a separation of chemicals that strongly initiate, and more or less markedly promote, hepatocarcinogenesis from those preferentially promoting this process.
There is no doubt that the initial administration of DEN renders the system more sensitive for the detection of carcinogenic compounds, but the unequivocal separation of 2 types of compounds, usually classified as initiators and promotors, remains a problem at the level of FAH, because at least the majority of chemical hepatocarcinogens seems to have both initiating and promoting activity, which may differ in quantitative rather than qualitative terms from one compound to the other (8) .
In this context, the hypothesis that many chemicals that have not been shown to interact with DNA might promote spontaneous FAH should be mentioned (30) . As long as the initial molecular events of carcinogenesis remain undetectable in situ, this hypothesis can neither be proven nor disproven. If spontaneous FAH are actually present, however, there is at present no way of excluding the possibility that DNA-reactive compounds likewise promote these preexisting FAH. Consequently, in studies on whole animals the determination of both the promoting and the initiating activity of hepatocarcinogens is fraught with uncertainties (7) , which can only be eliminated by a better understanding of the mechanism of action of carcinogens.
Whereas genetic mutations have been predominantly postulated to initiate hepatocarcinogenesis for many years (15, 27) , more recently epigenetic changes have been increasingly discussed as a plausible cause of the evolution of preneoplastic FAH characterized by metabolic changes (4, 21) , including the expression of GSTP (13, 28) . With respect to peroxisome proliferators the application of the protocol proposed by Oesterle et al (26) had the same false-negative result (16) as the medium-term carcinogenesis bioassay used by Ito et al (18) . The observation that some peroxisome proliferators including dehydroepiandrosterone (5) , and particularly T 3 (23) , inhibit hepatocarcinogenesis under certain experimental conditions implies, however, that a reduction in the area fraction of FAH by such compounds (19, 22) actually indicates a preventive potential, the possible application of which to patients remains to be clarified under well-controlled clinical conditions.
Relevance of Hepatic Preneoplasia for Human Hepatocarcinogensis
The detection of phenotypically similar FAH in various animal models and in the human liver does not only favor extrapolations from data obtained in animals to humans, but also opens new perspectives for secondary prevention of human HCC, the development of which has been estimated to take 30-50 years (6) . The main shortcoming for utilization of this long lag period for early detection of preneoplastic FAH and secondary prevention of human HCC is the small size of the lesions and their location in an organ that is not easily accessible. Thus, the majority of the early preneoplastic FAH are smaller than a liver lobule that has an average diameter of 1-2 millimeters in both rodents and humans. This small size precludes a noninvasive identification by all imaging procedures available. However, first efforts to diagnose at least certain types of FAH in fine-needle biopsies of the liver are promising, and may eventually result in an improvement of clinical approaches to monitor the manifestation of HCC in chronic liver diseases (31) . Another aspect of experimental hepatocarcinogenesis that might help to solve diagnostic and epidemiological problems in the human population, is the diagnosis of nodular lesions composed of phenotypically altered hepatocytes resembling those in FAH (32) .
Although the classification of such nodular liver lesions in rodents as hyperplastic or neoplastic has remained controversial, persistent nodules of this type are considered neoplasms, designated as adenomas (8) . In human pathology, the situation appears to be paradoxical because adenomas are only diagnosed in the noncirrhotic liver, yet a confusing variety of terms avoiding the clearcut classification as an adenoma has been created for nodular lesions in liver cirrhoses, notwithstanding the general agreement that the vast majority of HCC develop in cirrhotic livers (2) . Even if only a proportion of these nodular lesions would be regarded as adenomas, being integrated into an adenoma-carcinoma sequence as observed in many animal experiments, clinical and epidemiological records of liver neoplasms, including both benign and malignant forms, would increase considerably. This would not only bring hepatic neoplasia further into focus of human neoplasia in general, but also shed new light on the classification of some chemicals producing a high incidence of liver neoplasms in rodents, but appearing harmless for humans according to epidemiological evaluations solely based on the incidence of HCC in exposed populations.
